Skip to content
Finance Investment, Oil Mining Resources

LTR Pharma (ASX:LTP) SPONTAN® pivotal clinical study completes recruitment and dosing

LTR Pharma Limited (ASX:LTP) 2 mins read

Melbourne, Australia – LTR Pharma Limited (ASX:LTP), a leading pharmaceutical company, is excited to announce the successful completion of recruitment and dosing phases in its pivotal clinical study of SPONTAN®, a revolutionary nasal spray designed to treat erectile dysfunction (ED). This marks a significant milestone in the development of SPONTAN, setting the stage for a mid-2024 data read-out.

SPONTAN represents a world-first in ED treatment, offering a fast-acting, on-demand solution for those affected by this condition. Unlike traditional oral tablets, SPONTAN’s innovative nasal delivery technology ensures rapid absorption, bypassing the digestive system and providing a significantly faster onset of action within 10 minutes.

The study focused on evaluating the relative bioavailability of SPONTAN compared to the oral administration of Vardenafil, a widely recognized PDE5 inhibitor. This comparison is crucial in demonstrating the unique benefits and effectiveness of SPONTAN as a novel treatment option for ED.

With the recruitment and dosing stages now behind, the company has commenced the data analysis phase. The results from this study are eagerly anticipated and are expected to be released in mid-2024. These findings will play a vital role in the pre-submission meetings with the FDA and the introduction of SPONTAN into the market through Australia’s early access scheme.

LTR Pharma is committed to revolutionizing the treatment of ED and improving the quality of life for individuals affected by this condition. The completion of this phase brings us one step closer to making SPONTAN available to those in need, offering a discreet, efficient, and innovative solution to ED.

LTR Pharma Chairman, Lee Rodne, said: "With recruitment and dosing now complete, we thank the participants and our partners for contributing to this critical study. We are the first and only nasal spray coming to market for the treatment of Erectile Dysfunction and are extremely excited to bring this key innovation to men worldwide. We are now entering the data analysis phase. We believe SPONTAN represents a large paradigm shift in the treatment for Erectile Dysfunction and is a disruptor to the global blockbuster PDE5 (Viagra, etc) market.”


About us:

LTR Pharma is focused on improving men’s health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma’s lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.


Contact details:

Jane Morgan

jm@janemorganmanagement.com.au

Media

More from this category

  • Community, Finance Investment
  • 17/04/2024
  • 11:28
Communico Media Group P/L

Place Branding Australia 2024 to Illuminate Vivid Sydney

FOR IMMEDIATE RELEASE Sydney, Australia – April 18, 2024 – Place Branding Australia 2024, the premier conference on placemaking and community identity, will be a highlight of this year's Vivid Sydney festival. The conference will delve into how communities across Australia and beyond use their unique identities to drive economic and social growth, attract residents, and overcome challenges. "Vivid Sydney is the ideal backdrop for exploring the power of place branding," says conference curator Stu Speirs. "The festival's success is a testament to its deep connection with Sydney's identity as a place. This conference offers a front-row seat to a…

  • Finance Investment, Medical Health Aged Care
  • 17/04/2024
  • 11:12
Little Green Pharma

Medicinal cannabis company Little Green Pharma (ASX:LGP) records record quarterly revenue and cash receipts

RECORD REVENUE AND CASH RECEIPTS FOR QUARTER AND FINANCIAL YEAR, POSITIVE OPERATING CASHFLOW FOR FY24 OF $0.5 MILLION Highlights Record quarterly cash receipts of…

  • Contains:
  • Finance Investment, Oil Mining Resources
  • 17/04/2024
  • 10:12
Pantera Minerals Limited (ASX: PFE)

Pantera Minerals (ASX: PFE) – 1,500 New Acres added within the Primary Lithium Target Area

April 17, 2024 – ASX listed minerals explorer, Pantera Minerals Limited (ASX: PFE) is pleased to announce the successful leasing of an additional 1,500…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.